Literature DB >> 7023667

Surgery for common epithelial tumors of the ovary.

J T Wharton, J Herson.   

Abstract

The objectives of the initial surgical procedure in patients with common epithelial carcinomas of the ovary are determination of the intraabdominal extent of the cancer and the reduction of tumor masses to the smallest residuum before initiating further therapy. Since ovarian cancer is a disease of the entire abdominal cavity, biopsy of selected sites will often detect unsuspected involvement by microscopic foci of metastatic carcinoma. Tumor-reductive surgery resulting in a small tumor residuum before initiating chemotherapy is thought to improve the changes for inducing a complete response. The retroperitoneal operative approach enhances the surgeon's effort to remove tumor bulk. Between July 1, 1972, and September 1, 1978, 104 patients with FIGO Stage III or IV carcinomas of the ovary were treated with melphalan. The conditions of 38 patients were evaluated by second-look laparotomy. This analysis attempts to define tumor-reductive surgery and relates the outcome of the results of the operative procedure to patients treated with melphalan.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7023667     DOI: 10.1002/1097-0142(19810715)48:1+<582::aid-cncr2820481323>3.0.co;2-c

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

1.  [Surgical therapy of ovarian cancer].

Authors:  A Pfleiderer
Journal:  Arch Gynecol Obstet       Date:  1987       Impact factor: 2.344

2.  Diagnosis and staging of ovarian cancer.

Authors:  A Pfleiderer
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

3.  A study of the treatment of ovarian carcinoma.

Authors:  H Pickel
Journal:  Arch Gynecol       Date:  1983

4.  Hexamethylmelamine, adriamycin, and cyclophosphamide (HAC) versus cis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide (PAC) in advanced ovarian cancer: a randomized clinical trial.

Authors:  C Sessa; G Bolis; N Colombo; M D'Incalci; B Mermillod; I Valente; C Mangioni
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

5.  The prognostic value of morphometrical features and cellular DNA content in cis-platin treated late ovarian cancer patients.

Authors:  J P Baak; N W Schipper; E C Wisse-Brekelmans; T Ceelen; F T Bosman; H van Geuns; J Wils
Journal:  Br J Cancer       Date:  1988-05       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.